A Case of Acute Myeloid Leukemia Caused by Low Dose Methotrexate Used to Treat a Rheumatoid Arthritis Patient
Journal Title: Iranian Journal of Blood and Cancer - Year 2012, Vol 5, Issue 1
Abstract
Methotrexate is an anti-rheumatic agent used as a first-line tretment for rheumatoid arthritis. Hematological malignancies like lymphoma or acute myeloid leukemia have been reported to be secondary to treatment with Methotrexate, but are very uncommon. We report here the first Moroccan case of RA patient on low dose MTX, who developed AML. We also reviewed all similar cases.
Authors and Affiliations
Soumaya Anoun, Mouna Lamchahab, Meriem Qachouh, Said Benchekroun, Asmae Quessar
Keywords
Related Articles
- EP ID EP366206
- DOI -
- Views 64
- Downloads 0
Breast Cancer Associated with Dermatomyositis
Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy with characteristic skin lesions. Case series have shown an association between dermatomyositis and malignancy. Malignancy has been found in 15-25% of the a...
Retinoic Acid Syndrome: A Case Report and Review
Background: The treatment of acute promyelocytic leukemia with all-trans-retinoic acid (ATRA) sometimes results in a syndrome characterized by fever, respiratory distress, weight gain, pleural or pericardial effusion, an...
Hodgkin’s Lymphoma Occurring Secondary to Autologous Stem Cell Transplantation in Plasma Cell Leukemia; A Case Report
Survival of patients with multiple myeloma has improved substantially because of availability of new therapies including autotransplants, immunomodulating drugs and proteasome-inhibitors. Second primary cancers have emer...
Comparative Study of Four Platelet-Rich Plasma Methods for Preparing Platelet Concentrates
Background: Platelet preparations have been used for a wide variety of clinical applications such as hemorrhage, tissue engineering and cellular therapy. Platelet concentrates can be prepared by the apheresis method or f...
The First Discrete Choice Experiment On Usage of Bypassing Agents in Hemophilic Patients in Iran
Background: Bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. Currently available agents in Iran are recombinant activated factor VII (rfVIIa; Aryogen, Aryoseven) and Feiba (factor e...